FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
FATE THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.86+0.07 (+3.91%)
Close on Oct 19, 2026
- Market cap
- $223.94M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Fate Therapeutics has not reported a dividend
No dividend per share appears in Fate Therapeutics's annual filings since fiscal 2010.